Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Now clear those 0.0006's again ... ;)
Yes 0.0006's cleared .. now clear those 0.0007's ... :)))))))))))))))))))))))))))))))))))))))))
Let's clear those 0.0006 and 0.0007 now ... ;)
Let's GAP it UP at the open to 0.0006-0.0009 ... :)))))))))))))))))))))))))))))))))))))))))
Selling the GAP on Monday Morning 0.0006 and above ... :))))))))))))))))))))))))))))))))))))))
Loaded 65,342,987 shares on Friday ...
Indeed, I could not say it any better ... Credibility counts ...
Selling the TRIPS on the 0.0017 and above ... :)))))))))))))))))))))))))))))))))))))))))))))))))
Selling the GAP After Market ... :))))))))))))))))))))))))))))))))))))))))
$0.84 post liquidation value ...
Item 1.01. Entry into a Material Definitive Agreement.
As previously disclosed, Avalo Therapeutics, Inc. (the “Company”), entered into a Venture Loan and Security Agreement (as amended, from time to time, the “Note”), issued on June 4, 2021, to certain institutional investors (the “Holders”). As of July 20, 2023, the Holders asserted that a default and event of default has occurred due to a material adverse change in the Company’s business.
Also, as previously disclosed, on July 20, 2023, the Company entered into a Forbearance Agreement, which was subsequently amended by the Second Forbearance Agreement on August 14, 2023 (together, the “Prior Forbearance Agreements”) with the Holders. On September 13, 2023, the Company and the Holders entered into a Third Forbearance Agreement (the “Third Forbearance Agreement”) to, among other things, further extend the forbearance period until October 15, 2023. In exchange for the Holders agreeing to enter the Third Forbearance Agreement, the Company agreed to amend the Note to grant to the Holders a security interest in the Company’s owned patents and trademarks (the “Note Amendment”).
Except as set forth above, all other terms, conditions and rights of the Prior Forbearance Agreements, the Note, and the related transaction documents remain in full force and effect, which were described in the Current Report on Form 8-K filed on June 8, 2021, the Current Report on Form 8-K filed on July 21, 2023, and the Current Report on Form 8-K filed on August 14, 2023.
The foregoing descriptions of the Third Forbearance Agreement and the Note Amendment do not purport to be complete and are subject to, and qualified by, the full texts of such documents, copies of which are filed as Exhibit 10.1 and Exhibit 10.2, respectively, and are incorporated by reference herein.
Item 9.01. Financial Statements and Exhibits.
https://ih.advfn.com/stock-market/NASDAQ/avalo-therapeutics-AVTX/stock-news/92035025/form-8-k-current-report
Indeed, considering the market actions lately ...
Good Luck!
Selling the Huge GAP Pre Market @ 0.20 :)))))))))))))))))))))))))))))))))))))))))))))
Selling the GAP in the morning .... :))))))))))))))))))))))))))))))))))))))
Selling the huge GAP on the news ...
Sold ALL After Market @ 3.45 ... Thank you! :))))))))))))))))))))))))))))))))))))
Beautiful GAP ... :))))))))))))))))))))))))))))))
Selling the GAP Pre Market From 0.31 on Friday ... :)))))))))))
Selling the GAP Pre Market From 0.18 on Friday ... :))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
Thank you and Good Luck ...
Reloaded @ 0.18 for the next LEG ... ;)
Selling the beautiful GAP Pre Market ... :)))))))))))))))))))))))))))))))))))))))))))))))))))))))))
Beautiful HUGE GAP UP from 1.46 .... :)))))))))))))))))))))))))))))))))))))
Selling the Beautiful GAP @ 1.95 :))))))))))))))))))))))))))))
Selling ALL on the GAP Pre Market on Monday ... :)))))))))))))))))))))))))))))))
Selling the GAP ... :)))))))))))))))))))))))))))))))))))))))))
Selling the GAP ... 110% :)))))))))))))))))))))))
NVOS
COME ON, LET'S GOOOOOOOOOOOOO ...
RITE[/b
LET'S CLEAR 0.0008 AND 0.0009 ... RITE[/b
LOADED HEAVY YESTERDAY AND TODAY ...
LET'S GOOOOOOOOOOOOOOOOOOOOOOO ...
RITE
FINALLY ASK SIZE IS DECREASING ... :)))))))))))))))))))))))))))))))))
RMRK
LET'S GOOOOOOOOOOOOOOOOOOOO ...
RMRK
LET'S CLEAR THOSE 0.0007's TODAY ... ;)
RMRK
CLEAR ALL 0.0007's TODAY ... ;)
RMRK
LET'S GO AND CLEAR THOSE 0.0007 ... ;)
RMRK
YES ... LET'S CLEAR THOSE 0.0007... ;)
RMRK
LET'S GOOOOOOOOOOOOOOOOOOOO ...
RMRK
LOADED HEAVY LAST WEEK FOR THE UPCOMING MERGER ...
LET'S CLEAR 0.0006 AND 0.0007 TODAY ... ;)
RMRK
It looks like dilution has ceased for now ...
We will see the next few weeks ...
Good luck to you either way ...
GXXM
EMED SECURITY DETAILS
Share Structure
Market Cap Market Cap
694,784
06/22/2023
Authorized Shares
1,999,000,000
06/22/2023
Outstanding Shares
434,239,893
06/22/2023
Restricted
134,879,412
06/22/2023
Unrestricted
299,360,481
06/22/2023
Held at DTC
290,822,000
06/22/2023
Float
103,178,975
03/26/2023
Par Value
0.00001
https://www.otcmarkets.com/stock/EMED/security
My Bid is in there since last week ... ;)
GXXM